Advertisement

Topics

Sympore GmbH Company Profile

11:31 EST 22nd November 2017 | BioPortfolio

Sympore is a pharmaceutical discovery enterprise focusing on the mechanisms by which drugs enter and move through the body. Sympore uses its insights to modify compounds for improved uptake and distribution thus increasing efficacy and reducing side effects. To achieve significant improvements in bioavailability, Sympore employs pro-drug strategies and has identified a series of promising carriers that confer excellent uptake properties on their drug cargo. These carriers have demonstrated utility for compounds with a variety of modes of action from diverse structural classes.

Sympore has applied its technology to the improvement of compunds useful in inflammatory and autoimmune disease and has discovered two canditates with in vivio activity superior to marketed products. These projects have demonstrated the feasibility of dramatically improving compound properties over a timescale of weeks and of generating new profiles for known drugs.



Sympore´s business activities currently center on the improvement of compounds for internal projects. Based on the success of its carrier mediated approach, Sympore is also now interested in partnering with other firms to both further develop ist compounds and also to pursue other improvement projects.

Location

Ferdinand-Lassalle-Strasse, 40
Reutlingen
72770
Germany

Contact

Phone: 0049 7121 509076
Fax: 0049 7121 509115
Email: gabi.sauter@sympore.com


News Articles [116 Associated News Articles listed on BioPortfolio]

Royalties under patent licence agreements: can they remain payable even if the licensed patents(s) are revoked or not practised? Lessons from Genentech Inc v Hoechst GmbH & Sanofi-Aventis Deutschland GmbH

Précis In its recent decision in Genentech Inc v Hoechst GmbH & Sanofi-Aventis Deutschland GmbH (7 July 2016), the Court of Justice of the EU (“CJEU”) has ruled that an obligati...

Endocyte licenses radioligand prostate cancer therapy from ABX GMBH

Endocyte Inc. received exclusive global rights to the radioligand therapeutic PSMA617 (177LuPSMA617) from ABX GMBH.

DGAP-News: GBC Kapital GmbH: Erfolgreich abgeschlossene Kapitalmaßnahme der SYGNIS AG - beide Kapitalerhöhungen wurden von der GBC Kapital GmbH und der MC Services AG, jeweils als Co-Lead Manager Institutional Sales, begleitet und waren signifikant

GBC Kapital GmbH: Erfolgreich abgeschlossene Kapitalmaßnahme der SYGNIS AG - beide Kapitalerhöhungen wurden von der GBC Kapital GmbH und der MC Services AG, jeweils als Co-Lead Manager Institution.....

Körber Plans Takeover of Systec Services GmbH

     (Photo: http://mma.prnewswire.com/media/558312/SystecServices_Headquarters.jpg) With the planned takeover, Körber Medipak Systems GmbH, the holding company of Business Area Pharma Systems...

Evotec-Aktie: Q3/17 operativ beeindruckend - mehr Innovationen - Kaufen! Aktienanalyse

Frankfurt am Main - Evotec-Aktienanalyse von der EQUI.TS GmbH: Thomas J. Schießle und Daniel Großjohann, Aktienanalysten der EQUI.TS GmbH, raten in einer aktuellen Aktienanalyse weiterhin zum Kauf ....

Original-Research: Valneva SE (von First Berlin Equity Research GmbH): BUY

Original-Research: Valneva SE - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Valneva SE Unternehmen: Valneva SE ISIN: FR0004056851 Anlass der Studie: U...

Original-Research: Mologen AG (von First Berlin Equity Research GmbH): BUY

Original-Research: Mologen AG - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Mologen AG Unternehmen: Mologen AG ISIN: DE0006637200 Anlass der Studie: Q...

SyncDog Secures Distributor Partner Agreement with Germany-based EBF GmbH for EBF Migrator, EBF’s Platform for Accelerating EMM Migrations

Reston, VA (PRWEB) September 26, 2017 SyncDog, Inc. , the leading ISV for mobile application security, today announced a distributo...

PubMed Articles [15 Associated PubMed Articles listed on BioPortfolio]

Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study.

To evaluate safety (primary objective) and efficacy of increasing doses (400 U up to 800 U) of incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals GmbH) for patients with limb spasticity.

Biomechanical Characterization of Subclinical Keratoconus Without Topographic or Tomographic Abnormalities.

To present a case series of patients with subclinical keratoconus with normal topometric (anterior curvature) and tomographic findings in one eye who showed abnormalities detected by Corvis ST (Oculus...

Pulled-out locking screw re-screwed spontaneously in anterior cervical decompression and fusion with the zero-profile implant system: A case report.

The zero-profile, standalone device (Zero-P, Synthes GmbH, Switzerland) has been reported to be an effective and safe treatment method with similar clinical outcomes compared with plate. Instrumental ...

Cyclic and Torsional Fatigue Resistance of Reciprocating Single Files Manufactured by Different Nickel-titanium Alloys.

The aim of this study was to evaluate the cyclic and torsional fatigue resistance of the following reciprocating single-file systems: ProDesign R 25.06 (Easy Equipamentos Odontológicos, Belo Horizont...

Reliability of a Skin Diagnostic Device in Assessing Hydration and Erythema.

To examine the reliability of a skin diagnostic device, the SD202 (Courage+Khazaka GmBH, Cologne, Germany), in assessing hydration and erythema of periwound skin and pressure injury-prone areas.

Clinical Trials [39 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine

- Type: Bioequivalence study in male healthy volunteers, therapeutical indication (erectile disfunction) not studied - Products, dosage, and route of administration: ...

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

User Performance Evaluation of Contour® Plus One, Accu-Chek® Performa Connect, FreeStyle Optium Neo and OneTouch® Select Plus Blood Glucose Monitoring Systems Following ISO 15197:2013; EN ISO 15197:2015

The user performance evaluation shows whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system. In this study, user performance e...

Telemedical Examination of a Three-Component Oculomotor Testing Battery

The study investigates the feasibility and safety of the telemedical implementation of three diagnostic oculomotor tests using a video-oculography device and an extended teleconferencing s...

Influence of Non-invasive Neurostimulation (Transcutaneous Vagus Nerve Stimulation) on 1. the Noradrenergic Release in the Brain and 2. a Neuropsychological Memory Task

The goal of this study is to investigate the influence of transcutaneous vagus nerve stimulation 1. on the noradrenergic system in the brain and 2. on memory, in healthy volunteers. ...

Companies [523 Associated Companies listed on BioPortfolio]

Sympore GmbH

Sympore is a pharmaceutical discovery enterprise focusing on the mechanisms by which drugs enter and move through the body. Sympore uses its insights to modify compounds for improved uptake and distri...

Chemie-Kontor GmbH

Chemie-Kontor GmbH trades with chemical specialities for customers in Pharma-, Agro-, Cosmetics and Nutrition Industries and offers a broad range of services. Chemie-Kontor GmbH is agent for: Amberger...

OctreoPharm Sciences GmbH

OctreoPharm Sciences GmbH, located in Berlin (Germany) is a privately held clinical development company focusing on radiopharmaceuticals for the diagnosis and therapeutic control ...

Praher Beteiligungs GmbH

The vision of the company founder Ludwig Praher to produce better and better products of high-grade plastics was the basis for sound growth. Under the direction of Ing. Winfried Praher and Ewald Prahe...

Ormecon GmbH

Ormecon GmbH, with its location in Ammersbek/Germany, is the headquarter of Ormecon International. Ormecon GmbH was originally founded as "Ormecon Chemie GmbH & Co. KG" in 1996, as a 100% subsidiary o...

More Information about "Sympore GmbH" on BioPortfolio

We have published hundreds of Sympore GmbH news stories on BioPortfolio along with dozens of Sympore GmbH Clinical Trials and PubMed Articles about Sympore GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sympore GmbH Companies in our database. You can also find out about relevant Sympore GmbH Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...


Corporate Database Quicklinks



Searches Linking to this Company Record